Clinical Evaluation of T.R.U.E. TEST® : Safety and Efficacy

Inclusion Criteria: * Consecutive subjects must report symptoms and/or history consistent with allergic contact dermatitis to at least one of the allergens tested in the study (i.e., subjects are visiting the clinic/physician to diagnose, treat or resolve this condition). * Sensitive subjects must have a positive patch test to one of the following allergens within the past 10 years. * Gold sodium thiosulfate * Methyldibromoglutaronitrile (alone or with phenoxyethanol) * Bacitracin * Bronopol * Disperse blue 106 (alone or with Disperse blue 124) * Parthenolide (or Compositae mix) * Hydrocortisone-17-butyrate * All subjects must be adults over 18 years of age, and otherwise in good health. * Premenopausal female subjects with childbearing potential must consent to a urine pregnancy test; urine test results must be negative for study inclusion. * Informed consent must be signed and understood by each subject, and consistent with all institutional, local and national regulations. Exclusion Criteria: * Subjects unable to meet inclusion requirements. * Women who are breastfeeding or pregnant. * Topical corticosteroid treatment during the last 7 days before visit 1 on or near the test area. * Systemic treatment with corticosteroids or other immunosuppressants during the last 7 days.before visit 1. * Subjects currently receiving (or received in the 21 days before visit 1) other investigational drugs, treatments or devices, or participating in another clinical study.…